Martel R R, Klicius J, Metcalf G, Rona G A
Agents Actions. 1984 Oct;15(3-4):403-12. doi: 10.1007/BF01972379.
The effect of prolonged treatment with etodolac (8 mg/kg) on the articular and bone pathology at the tibiotarsal joint associated with adjuvant arthritis in the rat has been studied and compared to the effects produced by treatment with naproxen (8 mg/kg) and ibuprofen (50 mg/kg). Drug effects were assessed by radiologic and histopathologic examinations. The effects on hindpaw edema, hindleg function, and body weight gain were also evaluated. Treatment was initiated on day 16 after adjuvant injection and continued for 28, 56 or 84 days. The degree of relapse which occurred after a 28 day period without treatment following 28 or 56 days of treatment was also assessed. Etodolac prevented the progression of the disease. Further, it appeared to diminish the incidence and severity of the lesions already present on day 16 before drug treatment began. All the parameters measured were improved and there was good agreement between the radiologic and histopathologic assessments of joint damage. At the doses used, the onset of drug activity was more rapid with etodolac than with either of the other two drugs. By comparison naproxen and ibuprofen inhibited the progression of joint damage, but neither drug consistently decreased the magnitude of the joint damage below that of day 16. With all three drugs there was less resurgence of disease symptoms when treatment was stopped after 56 days rather than 28 days of drug administration.
研究了依托度酸(8毫克/千克)长期治疗对大鼠佐剂性关节炎相关的胫跗关节关节和骨骼病理的影响,并与萘普生(8毫克/千克)和布洛芬(50毫克/千克)治疗产生的效果进行了比较。通过放射学和组织病理学检查评估药物效果。还评估了对后爪水肿、后腿功能和体重增加的影响。在佐剂注射后第16天开始治疗,并持续28、56或84天。还评估了在28天或56天治疗后28天无治疗期后发生的复发程度。依托度酸可预防疾病进展。此外,它似乎降低了在药物治疗开始前第16天已存在的病变的发生率和严重程度。所有测量参数均得到改善,关节损伤的放射学和组织病理学评估之间具有良好的一致性。在所使用的剂量下,依托度酸的药物活性起效比其他两种药物更快。相比之下,萘普生和布洛芬抑制关节损伤的进展,但两种药物均未持续将关节损伤程度降低至低于第16天的水平。使用所有三种药物时,在给药56天而非28天后停药时,疾病症状的复发较少。